Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma.


Journal Article

There is no data on safety and efficacy of a second course of ibritumomab tiuxetan. In this work, data on patients with B-cell NHL who were treated with two courses of ibritumomab tiuxetan were analyzed. Eighteen such patients were analyzed (age: 58 years, 48 - 91), with a median of four prior regimens (1 - 7), stem cell transplantation (n = 5), and radiation therapy (n = 6). After the first course, G3/4 neutropenia and thrombocytopenia was 35% and 41%; overall response rate (ORR) was 89%; time between courses was 16.6 months (6.0 - 42.7). After the second course, the incidence of G3/4 neutropenia and thrombocytopenia was 28% and 44%; and ORR 77%. There were no infectious or bleeding complications, secondary myelodysplastic syndromes, or leukemias. Retreatment with the ibritumomab tiuxetan regimen was well tolerated, with a safety profile similar to that of the first course. To conclude, patients who benefited from the first course of ibritumomab tiuxetan can benefit from retreatment.

Full Text

Cited Authors

  • Shah, J; Wang, W; Harrough, VD; Saville, W; Meredith, R; Shen, S; Mueh, J; Lister, J; Jasthy, S; Maggass, G; McKay, C; Krumdieck, R; Tharp, M; Winter, C; Gregory, S; Buchholz, W; Awasthi, S; Jacobs, S; Chung, H; Egner, J; Lobuglio, AF; Forero, A

Published Date

  • September 2007

Published In

Volume / Issue

  • 48 / 9

Start / End Page

  • 1736 - 1744

PubMed ID

  • 17786709

Pubmed Central ID

  • 17786709

Electronic International Standard Serial Number (EISSN)

  • 1029-2403

International Standard Serial Number (ISSN)

  • 1042-8194

Digital Object Identifier (DOI)

  • 10.1080/10428190701528517


  • eng